The Effect of Prostate Cancer Diagnosis on Adherence to Medications for Patients with Type 2 Diabetes

Muhammad Aamir Zaffar, Muhammad Fazeel Iqbal, Muhammad Rameez

Abstract


To date, few studies have explored whether being diagnosed with cancer interrupted medication adherence for their non-cancer chronic conditions.35-37 This study examined the effect of being diagnosed with prostate cancer on adherence to OHAs among patients with type 2 diabetes. Non-metastatic, lower-risk prostate cancer is an excellent case study for studying survivorship care because it is prevalent and has high survival rates; diabetes is important not only because of its prevalence but also its morbidity and associated health care costs. This study hypothesized that patients would become less adherent to their OHAs during the first year post–prostate cancer diagnosis compared to their pre-diagnosis adherence levels, however their adherence would return to similar rates during the second year after being diagnosed. This study found that patients diagnosed with prostate cancer did have decreased adherence when compared with controls in the period immediately following cancer-diagnosis; however, contrary to our hypothesis, adherence to their diabetes medications never returned to pre-diagnosis levels. A similar decline was observed among all stages of prostate cancer patients during the 6 months post-diagnosis.17 However, our current study had a longer follow-up period (2 years vs. 6 months post– cancer diagnosis) and more years of data. In addition, This study only included patients with non-metastatic prostate cancer, a group for whom managing comorbidities would be a higher priority than patients with more aggressive cancer. The finding that diabetes patients diagnosed with a highly survivable cancer have decreased adherence to their diabetes medications two years after diagnosis is concerning. Certainly, primary care physicians and oncologists should not necessarily assume that their patients with chronic diseases will return to their baseline medication adherence levels after completing cancer treatments, particularly when patients believe controlling their diabetes or other chronic conditions is not as necessary as it truly is.38 Given the morbidity and mortality from non-cancer chronic conditions, providers should actively emphasize the importance of taking all medications.


Keywords


Non-metastatic prostate, type 2 diabetes, OHAs

Full Text:

PDF

References


National Diabetes Statistics Report, 2014. The Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report- web.pdf. Accessed 2.3.2016.

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. ‘Number of Americans with diabetes projected to double or triple by 2050. http://www.cdc.gov/media/pressrel/2010/r101022.html. Accessed March 14, 2016.

National Diabetes Statistics 2011. National Diabetes Information Clearinghouse.

http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#fast. Accessed October 5, 2016.

U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet. 1998. www.ComprehensiveDiabetesCare.gov/diabetes/pubs/facts98.htm. Accessed October 20, 2016.

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497.

Cramer, J. A. (2004). A systematic review of adherence with medications for diabetes.

Diabetes Care, 27(5), 1218-1224.

Pladevall, M., Williams, L. K., Potts, L. A., Divine, G., Xi, H., & Lafata, J. E. (2004). Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care, 27(12), 2800-2805. doi:27/12/2800 [pii]

Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner,

J. F., & Magid, D. J. (2006). Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Archives of Internal Medicine, 166(17), 1836-1841.

Bradley, C. J., Dahman, B., & Anscher, M. (2014). Prostate cancer treatment and survival: Evidence for men with prevalent comorbid conditions. Medical Care, 52(6), 482-489.

American Cancer Society. Cancer Treatment and Survivorship Facts & Figures 2012- 2013. Atlanta: American Cancer Society; 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu ment/acspc-033876.pdf. Accessed April 6, 2016.

Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2016. http://seer.cancer.gov/csr/1975_2000. Accessed October 10, 2016.

Ning, Y., Shen, Q., Herrick, K., Mikkelsen, R., Anscher, M., Houlihan, R., & Lapane, K. (2012). Abstract LB-339: Cause of death in cancer survivors. Cancer Research, 72(8 Supplement), LB-339-LB-339.

Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–9

Zhang FF, Liu S, John EM, et al. Diet quality of cancer survivors and noncancer individuals: Results from a national survey. Cancer. 2015;121(23): 4212-4221.

Coups EJ, Ostroff JS. A population-based estimate of the prevalence of behavioral risk factors among adult cancer survivors and noncancer controls. Preventive Medicine. 2005; 40(6):702-711.

Ashing-Giwa KT, Padilla G, Tejero J, et al. Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian Cancer Survivors. Psychooncology. 2004. 13(6):408-428.

Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a diagnosis of cancer among beneficiaries with diabetes. Journal of Oncology Practice 2015; 11(6):429-434.

National Cancer Institute Surveillance, Epidemiology, and End Results Program; National Institutes of Health. http://healthcaredelivery.cancer.gov/seermedicare/overview/. Accessed 4.6.2016.

Cai M. Kappelman MD, Girman CJ, et al. Trends and determinants of oral anti-diabetic initiation in youth with suspected type 2 diabetes. PLoS One. 2015. 10(10):e0140611.

Rasmussen NJ, Chong A, Alter DA. Relationship between adherence to evidence- based pharmacotherapy and long-term mortality after acute myocardial infarction.

JAMA. 2007;297(2):177-186.Ho PMH, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-3035.

American Diabetes Association. ‘Oral Medication.’ http://www.diabetes.org/living-with- diabetes/treatment-and-care/medication/oral-medications/what-are-my-options.html.Accessed 12.3.2016.

Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009; 15(7):457-464.

Department of Health and Human Services, Health Resource and Services Administration, Bureau of Health Professions, National Center for Health Workforce Analysis. ‘Area Resource File. ‘http://www.healthindicators.gov/Resources/DataSources/AHRF_18/Profile.’ Accessed 1.13.16.

National Cancer Institute Surveillance, Epidemiology, and End Results Program; National Institutes of Health. http://healthcaredelivery.cancer.gov/seermedicare/overview/. Accessed 4.6.2016.

National Cancer Institute Division of Cancer Control & Population Studies, Healthcare Delivery Research Program: SEER-Medicare: Calculation of Comorbidity Weights. http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html. Accessed 10.5.16.

Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000 Dec;53(12):1258-67.

Austin, Peter. A Comparison of 12 Algorithms for Matching on the Propensity Score. Stat Med 33: 1057-1069, 2014

Parsons, LS. Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. SUGI 26: Paper 214-26. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed 9.3.16.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research. 2001; 46(3): 399-424.

Rosenbaum, P. R. (2002). Observational studies (2nd ed.). New York, NY: Springer- Verlag.

Gillings, D, Makuc, D, Siegel, E (1981) Analysis of interrupted time series mortality trends: an example to evaluate regionalized perinatal care. American Journal of Public Health, 71, 38–46.

Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics (2002). 27:299-309.

Lewey J, Shrank WH, Avorn J, et al. Medication adherence and healthcare disparities: impact of statin co-payment reduction. Am J Managed Care. 2015. 21(10): 696-704.

Treanor, C., & Donnelly, M. (2012). An international review of the patterns and determinants of health service utilisation by adult cancer survivors. BMC Health Services Research, 12, 316-6963-12-316. doi:10.1186/1472-6963-12-316 [doi]

Keating NL, Liu P-H, O’Malley AJ, et al. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. European Oncology 2014; 65:816- 824.

Calip GS, Hubbard RA, Stergachis A, et al: Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24:75-85, 2015

Mann DM, Ponieman D, Leventhal H, et al. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med. 2009. 32:278- 284.

Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative data among diabetic patients. Medical Care.2008;46(11):1125-1133.

Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149- 2153.

Weinstock RS, Teresi JA, Goland R, et al. Glycemic control and health disparities in older ethnically diverse underserved adults with diabetes: Five-year results from the Informatics for Diabetes Education and Telemedicine (IDEATel) study. Diabetes Care. 2011. 34(2):274-279.

Keating, N.L. et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24(27), 4448–4456.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.